I recall an interview with Leslie Ching of IMU when asked about Big Pharma interest her response was along the lines of it all depends on where or if your product fits into their pipeline, so all you can do is keep proving up the science.
That's the big question for any biotech but for SPL who have been in big pharma stable for a long time just where does DEP fit into the pipeline?
For big pharma to throw up a couple of posters at a conference keeping the carrot dangling is just a pat on the head keep working away boys and girls we just might need you one day if we cannot get our hands on what we're really after.
The strides being taken in the immune space (CART & NK platforms) is the challenge for DEP in the cancer market it's been focused on for so long.
SPL Price at posting:
$1.32 Sentiment: None Disclosure: Held
